Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.

导出 OA

翻译打印收藏纠错

第一作者： Curtis R,Heberle

第一单位： Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts.

作者： Curtis R,Heberle ^[1] ; Amir-Houshang,Omidvari ^[2] ; Ayman,Ali ^[1] ; Sonja,Kroep ^[2] ; Chung Yin,Kong ^[3] ; John M,Inadomi ^[4] ; Joel H,Rubenstein ^[5] ; Angela C,Tramontano ^[6] ; Emily C,Dowling ^[6] ; William D,Hazelton ^[7] ; E Georg,Luebeck ^[7] ; Iris,Lansdorp-Vogelaar ^[2] ; Chin,Hur ^[8]

作者单位： Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts. ^[1] Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands. ^[2] Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. ^[3] Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. ^[4] Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan; Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michigan. ^[5] Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts. ^[6] Program in Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[7] Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: chur@mgh.harvard.edu. ^[8]

关键词 Barrett’s Esophagus Cost Effectiveness Cytosponge Esophageal Adenocarcinoma